Autolus Therapeutics (AUTL) Cash from Operations (2017 - 2025)
Autolus Therapeutics posted quarterly Cash from Operations of 67323000.0 for Q4 2025, down 77.47% year-on-year from 298868423.87 in Q4 2024, and up 0.85% on a QoQ basis from 67899000.0 in Q3 2025.
Autolus Therapeutics (AUTL) has 9 years of Cash from Operations data on file, last reported at 67323000.0 in Q4 2025.
- For the quarter ending Q4 2025, Cash from Operations fell 77.47% year-over-year to 67323000.0; the trailing twelve-month figure through Dec 2025 stood at 283568000.0 (down 37.47% YoY), and the FY2025 full-year result was 283568000.0, down 37.47% from the prior year.
- Cash from Operations for Q4 2025 stood at 67323000.0, up from 67899000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 9158000.0 in Q4 2021 and bottomed at 76740000.0 in Q3 2024.
- The 5-year median for Cash from Operations is 38040500.0 (2023), against an average of 43279750.0.
- The widest annual swing landed in 2021, when Cash from Operations jumped 66.97%; it then sank 90.95% in 2024.
- A 5-year view of Cash from Operations shows it stood at 9158000.0 in 2021, then tumbled by 59.05% to 14566000.0 in 2022, then slumped by 70.49% to 24833000.0 in 2023, then tumbled by 52.76% to 37934000.0 in 2024, then slumped by 77.47% to 67323000.0 in 2025.
- The last three Cash from Operations figures came in at 67323000.0 (Q4 2025), 67899000.0 (Q3 2025), and 72781000.0 (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | -1.67 Mn |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | -12.20 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | -2.49 Mn |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | 1.43 Bn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | 1.08 Bn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | 70.50 Mn |
| 10 | Autolus Therapeutics | - | - | -1.04 Mn | -67.32 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -67.32 Mn |
| Dec 31, 2025 | -67.32 Mn |
| Sep 30, 2025 | -67.90 Mn |
| Sep 30, 2025 | -67.90 Mn |
| Jun 30, 2025 | -72.78 Mn |
| Jun 30, 2025 | -72.78 Mn |
| Mar 31, 2025 | -75.57 Mn |
| Mar 31, 2025 | -75.57 Mn |
| Dec 31, 2024 | -37.93 Mn |
| Dec 31, 2024 | -37.93 Mn |
| Sep 30, 2024 | -76.74 Mn |
| Sep 30, 2024 | -76.74 Mn |
| Jun 30, 2024 | -51.08 Mn |
| Jun 30, 2024 | -51.08 Mn |
| Mar 31, 2024 | -40.51 Mn |
| Mar 31, 2024 | -40.51 Mn |
| Dec 31, 2023 | -24.83 Mn |
| Dec 31, 2023 | -24.83 Mn |
| Sep 30, 2023 | -40.19 Mn |
| Sep 30, 2023 | -40.19 Mn |
| Jun 30, 2023 | -38.15 Mn |
| Jun 30, 2023 | -38.15 Mn |
| Mar 31, 2023 | -42.42 Mn |
| Mar 31, 2023 | -42.42 Mn |
| Dec 31, 2022 | -14.57 Mn |
| Dec 31, 2022 | -14.57 Mn |
| Sep 30, 2022 | -31.90 Mn |
| Sep 30, 2022 | -31.90 Mn |
| Jun 30, 2022 | -30.81 Mn |
| Jun 30, 2022 | -30.81 Mn |
| Mar 31, 2022 | -35.03 Mn |
| Mar 31, 2022 | -35.03 Mn |
| Dec 31, 2021 | -9.16 Mn |
| Dec 31, 2021 | -9.16 Mn |
| Sep 30, 2021 | -34.75 Mn |
| Sep 30, 2021 | -34.75 Mn |
| Jun 30, 2021 | -36.61 Mn |
| Jun 30, 2021 | -36.61 Mn |
| Mar 31, 2021 | -37.34 Mn |
| Mar 31, 2021 | -37.34 Mn |
| Dec 31, 2020 | -27.73 Mn |
| Dec 31, 2020 | -27.73 Mn |
| Sep 30, 2020 | -39.06 Mn |
| Sep 30, 2020 | -39.06 Mn |
| Jun 30, 2020 | -26.93 Mn |
| Jun 30, 2020 | -26.93 Mn |
| Mar 31, 2020 | -24.03 Mn |
| Mar 31, 2020 | -24.03 Mn |
| Jun 30, 2019 | -43.73 Mn |
| Jun 30, 2019 | -43.73 Mn |
| Mar 31, 2019 | -26.52 Mn |
| Mar 31, 2019 | -26.52 Mn |
| Sep 30, 2018 | -31.54 Mn |
| Sep 30, 2018 | -31.54 Mn |
| Jun 30, 2018 | -14.37 Mn |
| Jun 30, 2018 | -14.37 Mn |
| Mar 31, 2018 | -8.13 Mn |
| Mar 31, 2018 | -8.13 Mn |
| Dec 31, 2017 | -8.80 Mn |
| Dec 31, 2017 | -8.80 Mn |